What's Happening?
China's Ministry of Commerce (MOFCOM) and Ministry of Science and Technology (MOST) have issued Announcement No. 48 of 2026, proposing to add 40 technologies to its Catalogue of Technologies Prohibited and Restricted from Export. These technologies span
artificial intelligence (AI), biopharmaceuticals, and photovoltaics. Of the 40, 14 would be prohibited from export, and 26 would be restricted. Notably, interim pre-export registration for these listed technologies, including ongoing exports, has been in effect since October 16, 2026, even as comments on the proposal are due by November 15, 2026. The proposed controls differentiate between platform ownership and product licensing, creating a complex framework for technology transfers.
Why It's Important?
These proposed export controls are highly significant for U.S. companies involved in AI, biopharmaceuticals, and renewable energy sectors that have ties to China. The immediate implementation of pre-export registration means that businesses must navigate new compliance requirements for existing and future technology transfers. The distinction between platform ownership and product rights introduces complexity, requiring careful legal and strategic planning for collaborations, licensing agreements, and joint ventures. For U.S. firms, this could impact supply chains, research and development partnerships, and market access, potentially increasing operational costs and legal risks. It also reflects China's strategic intent to control critical technologies, mirroring similar actions by the U.S. and further contributing to technological decoupling.
What's Next?
Companies engaged in technology transfers with China, particularly in the AI and biopharma sectors, must immediately assess their current and planned activities against the new pre-export registration requirements. They will need to carefully review the specifics of the proposed restrictions and prohibitions to ensure compliance. Following the comment period, the final version of the Catalogue will be released, which may lead to further adjustments in business strategies. U.S. companies should anticipate increased scrutiny on technology exports from China and prepare for potential delays or denials of export licenses. This could also prompt a re-evaluation of global R&D and manufacturing footprints to mitigate risks associated with these controls.
Beyond the Headlines
Beyond the immediate regulatory impact, these export controls signify a deepening trend of technological nationalism and strategic competition between major global powers. China's move to restrict key technologies in AI and biopharma reflects a broader effort to secure its technological sovereignty and protect national interests, potentially in response to similar measures from the U.S. This could accelerate the fragmentation of global technology ecosystems, leading to parallel development paths and reduced international collaboration in critical scientific fields. The long-term implications include potential slowdowns in global innovation, increased costs for technological development, and heightened geopolitical tensions as countries vie for dominance in strategic industries. Ethical considerations around access to advanced medical technologies and the responsible development of AI will also become more pronounced in this fragmented landscape.
